EA034616B1 - СТАБИЛЬНЫЙ СОСТАВ В ВИДЕ РАСТВОРА АНТИТЕЛА HUM13B8-b К IL-23p19 И СПОСОБ ЛЕЧЕНИЯ АУТОИММУННОГО ЗАБОЛЕВАНИЯ, ВОСПАЛИТЕЛЬНОГО ЗАБОЛЕВАНИЯ ИЛИ ПРОЛИФЕРАТИВНОГО НАРУШЕНИЯ - Google Patents
СТАБИЛЬНЫЙ СОСТАВ В ВИДЕ РАСТВОРА АНТИТЕЛА HUM13B8-b К IL-23p19 И СПОСОБ ЛЕЧЕНИЯ АУТОИММУННОГО ЗАБОЛЕВАНИЯ, ВОСПАЛИТЕЛЬНОГО ЗАБОЛЕВАНИЯ ИЛИ ПРОЛИФЕРАТИВНОГО НАРУШЕНИЯ Download PDFInfo
- Publication number
- EA034616B1 EA034616B1 EA201591133A EA201591133A EA034616B1 EA 034616 B1 EA034616 B1 EA 034616B1 EA 201591133 A EA201591133 A EA 201591133A EA 201591133 A EA201591133 A EA 201591133A EA 034616 B1 EA034616 B1 EA 034616B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antibody
- hum13b8
- antibodies
- sequence
- formulations
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 101
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 22
- 208000035475 disorder Diseases 0.000 title claims abstract description 20
- 208000023275 Autoimmune disease Diseases 0.000 title claims abstract description 14
- 230000002062 proliferating effect Effects 0.000 title claims abstract description 14
- 208000037979 autoimmune inflammatory disease Diseases 0.000 title claims abstract description 7
- 238000000034 method Methods 0.000 title claims description 12
- 238000009472 formulation Methods 0.000 title abstract description 49
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims abstract description 26
- 239000000872 buffer Substances 0.000 claims abstract description 23
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 22
- 229930006000 Sucrose Natural products 0.000 claims abstract description 17
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 17
- 239000005720 sucrose Substances 0.000 claims abstract description 17
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims abstract description 16
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims abstract description 15
- 229920000053 polysorbate 80 Polymers 0.000 claims abstract description 15
- 229940068968 polysorbate 80 Drugs 0.000 claims abstract description 15
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 14
- 229920001184 polypeptide Polymers 0.000 claims abstract description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims abstract description 5
- 239000000243 solution Substances 0.000 claims description 53
- 108010076561 Interleukin-23 Subunit p19 Proteins 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 25
- 238000002347 injection Methods 0.000 claims description 10
- 239000007924 injection Substances 0.000 claims description 10
- 238000007920 subcutaneous administration Methods 0.000 claims description 8
- 201000004681 Psoriasis Diseases 0.000 claims description 5
- 229940090047 auto-injector Drugs 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 102000011718 Interleukin-23 Subunit p19 Human genes 0.000 claims 2
- 102000013264 Interleukin-23 Human genes 0.000 abstract description 37
- 108010065637 Interleukin-23 Proteins 0.000 abstract description 37
- 229940124829 interleukin-23 Drugs 0.000 abstract description 35
- 238000011993 High Performance Size Exclusion Chromatography Methods 0.000 description 36
- 238000003860 storage Methods 0.000 description 35
- 235000018102 proteins Nutrition 0.000 description 32
- 108090000623 proteins and genes Proteins 0.000 description 32
- 102000004169 proteins and genes Human genes 0.000 description 32
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 30
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 29
- 229960002885 histidine Drugs 0.000 description 27
- 230000004071 biological effect Effects 0.000 description 24
- 239000000178 monomer Substances 0.000 description 24
- 102100036705 Interleukin-23 subunit alpha Human genes 0.000 description 23
- 239000000523 sample Substances 0.000 description 23
- 230000027455 binding Effects 0.000 description 22
- 239000002253 acid Substances 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 21
- 230000010494 opalescence Effects 0.000 description 21
- -1 HMW compound Chemical class 0.000 description 20
- 230000000694 effects Effects 0.000 description 20
- 229940079593 drug Drugs 0.000 description 19
- 238000012360 testing method Methods 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 17
- 238000002965 ELISA Methods 0.000 description 16
- 206010028980 Neoplasm Diseases 0.000 description 16
- 150000002605 large molecules Chemical class 0.000 description 16
- 238000000113 differential scanning calorimetry Methods 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 15
- 230000001225 therapeutic effect Effects 0.000 description 15
- 230000015556 catabolic process Effects 0.000 description 14
- 238000006731 degradation reaction Methods 0.000 description 14
- 238000002296 dynamic light scattering Methods 0.000 description 13
- 238000010828 elution Methods 0.000 description 13
- 238000010521 absorption reaction Methods 0.000 description 12
- 230000002776 aggregation Effects 0.000 description 12
- 238000004220 aggregation Methods 0.000 description 12
- 239000000427 antigen Substances 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 11
- 229940024606 amino acid Drugs 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 11
- 150000001413 amino acids Chemical class 0.000 description 11
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 10
- 108010065805 Interleukin-12 Proteins 0.000 description 10
- 102000013462 Interleukin-12 Human genes 0.000 description 10
- 238000010230 functional analysis Methods 0.000 description 10
- 210000004602 germ cell Anatomy 0.000 description 10
- 229940117681 interleukin-12 Drugs 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- 238000003776 cleavage reaction Methods 0.000 description 9
- 208000027866 inflammatory disease Diseases 0.000 description 9
- 238000013112 stability test Methods 0.000 description 9
- 241000282412 Homo Species 0.000 description 8
- 108010076504 Protein Sorting Signals Proteins 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 238000012510 peptide mapping method Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 230000007017 scission Effects 0.000 description 8
- 150000003384 small molecules Chemical class 0.000 description 8
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 229940043131 pyroglutamate Drugs 0.000 description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
- 239000004472 Lysine Substances 0.000 description 6
- 229940125644 antibody drug Drugs 0.000 description 6
- 230000006652 catabolic pathway Effects 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- 230000003647 oxidation Effects 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 206010003246 arthritis Diseases 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 238000001542 size-exclusion chromatography Methods 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 4
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 230000001363 autoimmune Effects 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- 201000006417 multiple sclerosis Diseases 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 230000007704 transition Effects 0.000 description 4
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 description 3
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 description 3
- 206010009900 Colitis ulcerative Diseases 0.000 description 3
- 208000011231 Crohn disease Diseases 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 208000009329 Graft vs Host Disease Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- 102000013691 Interleukin-17 Human genes 0.000 description 3
- 108050003558 Interleukin-17 Proteins 0.000 description 3
- 101001018085 Lysobacter enzymogenes Lysyl endopeptidase Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229910002651 NO3 Inorganic materials 0.000 description 3
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 3
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 3
- 102000003992 Peroxidases Human genes 0.000 description 3
- 208000037581 Persistent Infection Diseases 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 3
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 229960002964 adalimumab Drugs 0.000 description 3
- 238000007112 amidation reaction Methods 0.000 description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 3
- 238000013103 analytical ultracentrifugation Methods 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 238000000149 argon plasma sintering Methods 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 238000005251 capillar electrophoresis Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 239000005038 ethylene vinyl acetate Substances 0.000 description 3
- 238000013467 fragmentation Methods 0.000 description 3
- 238000006062 fragmentation reaction Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 208000024908 graft versus host disease Diseases 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000004255 ion exchange chromatography Methods 0.000 description 3
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000000569 multi-angle light scattering Methods 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 229940068977 polysorbate 20 Drugs 0.000 description 3
- 229940071643 prefilled syringe Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000012925 reference material Substances 0.000 description 3
- 229960004641 rituximab Drugs 0.000 description 3
- 238000004062 sedimentation Methods 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 229960003824 ustekinumab Drugs 0.000 description 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 206010058314 Dysplasia Diseases 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 2
- 101000852980 Homo sapiens Interleukin-23 subunit alpha Proteins 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 2
- 206010062207 Mycobacterial infection Diseases 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 2
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 229960000548 alemtuzumab Drugs 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000003749 cleanliness Effects 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000006240 deamidation Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 2
- 229960005386 ipilimumab Drugs 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 208000027531 mycobacterial infectious disease Diseases 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 238000013356 sedimentation velocity analytical ultracentrifugation Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- IJJWOSAXNHWBPR-HUBLWGQQSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(6-hydrazinyl-6-oxohexyl)pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)NN)SC[C@@H]21 IJJWOSAXNHWBPR-HUBLWGQQSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 description 1
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 description 1
- 102100036848 C-C motif chemokine 20 Human genes 0.000 description 1
- 102100032366 C-C motif chemokine 7 Human genes 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- XZWYTXMRWQJBGX-VXBMVYAYSA-N FLAG peptide Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 XZWYTXMRWQJBGX-VXBMVYAYSA-N 0.000 description 1
- 108010020195 FLAG peptide Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 description 1
- 101000797758 Homo sapiens C-C motif chemokine 7 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 102100036672 Interleukin-23 receptor Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000000704 Interleukin-7 Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- GHAZCVNUKKZTLG-UHFFFAOYSA-N N-ethyl-succinimide Natural products CCN1C(=O)CCC1=O GHAZCVNUKKZTLG-UHFFFAOYSA-N 0.000 description 1
- HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 208000006994 Precancerous Conditions Diseases 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 229960000446 abciximab Drugs 0.000 description 1
- 230000032912 absorption of UV light Effects 0.000 description 1
- 238000004847 absorption spectroscopy Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012615 aggregate Substances 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 229960003115 certolizumab pegol Drugs 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 208000020947 enthesitis Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 229960001743 golimumab Drugs 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000037189 immune system physiology Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 108040001844 interleukin-23 receptor activity proteins Proteins 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000006338 isoaspartate formation Effects 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012886 linear function Methods 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 229960005027 natalizumab Drugs 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229960000402 palivizumab Drugs 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 229960002087 pertuzumab Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 230000007824 polyneuropathy Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 229960003876 ranibizumab Drugs 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000011191 terminal modification Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 229940126622 therapeutic monoclonal antibody Drugs 0.000 description 1
- 230000010512 thermal transition Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000012784 weak cation exchange Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261737035P | 2012-12-13 | 2012-12-13 | |
| PCT/US2013/073825 WO2014093203A1 (en) | 2012-12-13 | 2013-12-09 | SOLUTION FORMULATIONS OF ENGINEERED ANTI-IL-23p19 ANTIBODIES |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201591133A1 EA201591133A1 (ru) | 2015-10-30 |
| EA034616B1 true EA034616B1 (ru) | 2020-02-27 |
Family
ID=50934859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201591133A EA034616B1 (ru) | 2012-12-13 | 2013-12-09 | СТАБИЛЬНЫЙ СОСТАВ В ВИДЕ РАСТВОРА АНТИТЕЛА HUM13B8-b К IL-23p19 И СПОСОБ ЛЕЧЕНИЯ АУТОИММУННОГО ЗАБОЛЕВАНИЯ, ВОСПАЛИТЕЛЬНОГО ЗАБОЛЕВАНИЯ ИЛИ ПРОЛИФЕРАТИВНОГО НАРУШЕНИЯ |
Country Status (31)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI806150B (zh) | 2014-11-07 | 2023-06-21 | 瑞士商諾華公司 | 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物 |
| JP7179717B2 (ja) * | 2017-03-31 | 2022-11-29 | Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 | 水性製剤及び注射器入り水性製剤、並びに、抗体タンパク脱凝集剤及び抗体タンパク脱凝集方法 |
| MX2020009265A (es) * | 2018-03-05 | 2020-10-01 | Janssen Biotech Inc | Metodos para tratar la enfermedad de crohn con un anticuerpo especifico anti-il23. |
| SG11202104166QA (en) * | 2018-11-21 | 2021-05-28 | Regeneron Pharma | High concentration protein formulation |
| CN112334483B (zh) | 2018-11-27 | 2022-05-10 | 信达生物制药(苏州)有限公司 | 抗IL-23p19抗体及其用途 |
| US12493019B2 (en) | 2019-02-20 | 2025-12-09 | Amgen Inc. | Methods of determining protein stability |
| AU2020279987A1 (en) | 2019-05-23 | 2021-11-18 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha |
| US20210070852A1 (en) * | 2019-09-09 | 2021-03-11 | Boehringer Ingelheim International Gmbh | Anti-IL-23p19 Antibody Formulations |
| US11396541B2 (en) | 2019-12-20 | 2022-07-26 | Novarock Biotherapeutics, Ltd. | Anti-interleukin-23 P19 antibodies and methods of use thereof |
| BR112022022919A2 (pt) * | 2020-05-13 | 2022-12-20 | Innovent Biologics Suzhou Co Ltd | Formulação compreendendo o anticorpo anti-il-23p19, método para preparar o mesmo e uso do mesmo". |
| CA3183927A1 (en) | 2020-05-21 | 2021-11-25 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha |
| WO2025071362A1 (ko) * | 2023-09-27 | 2025-04-03 | 삼성바이오에피스 주식회사 | 항-il-23 항체의 안정한 액상 제형 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090311253A1 (en) * | 2008-06-03 | 2009-12-17 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| US20110229490A1 (en) * | 2008-08-27 | 2011-09-22 | Schering Corporation | Lyophilized Formulations of Engineered Anti-IL-23p19 Antibodies |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2366706A1 (en) | 1999-03-11 | 2000-09-14 | Schering Corporation | Mammalian cytokines; related reagents and methods |
| JP4505166B2 (ja) | 1999-09-09 | 2010-07-21 | シェーリング コーポレイション | 哺乳動物インターロイキン−１２ｐ４０およびインターロイキンｂ３０、その組成物、抗体、薬学的組成物における使用 |
| DE60235013D1 (de) | 2001-07-25 | 2010-02-25 | Facet Biotech Corp | Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab |
| CA2466034C (en) * | 2001-11-08 | 2012-12-18 | Protein Design Labs, Inc. | Stable aqueous pharmaceutical formulations of daclizumab antibodies |
| US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| WO2004071517A2 (en) | 2003-02-06 | 2004-08-26 | Schering Corporation | Uses of il-23 related reagents |
| DK2236154T3 (en) | 2003-02-10 | 2018-06-25 | Biogen Ma Inc | IMMUNOGLOBULIN INFORMATION AND METHOD OF PREPARING IT |
| EP1601694B1 (en) | 2003-03-10 | 2009-08-26 | Schering Corporation | Uses of il-23 antagonists; related reagents |
| BRPI0403964B8 (pt) * | 2003-04-04 | 2021-05-25 | Genentech Inc | formulações líquidas estáveis, artigo manufaturado e uso dessas formulações para o tratamento de disfunção mediada por ige |
| WO2005079837A1 (en) | 2004-02-17 | 2005-09-01 | Schering Corporation | Methods of modulating il-23 activity; related reagents |
| WO2005117967A2 (en) | 2004-04-12 | 2005-12-15 | Medimmune, Inc. | Anti-il-9 antibody formulations and uses thereof |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| GT200600031A (es) | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
| HRP20130400T1 (en) | 2005-06-30 | 2013-06-30 | Janssen Biotech, Inc. | Anti-il-23 antibodies, compositions, methods and uses |
| SI1937721T1 (sl) | 2005-08-25 | 2010-11-30 | Lilly Co Eli | Anti il protitelesa |
| DK1931710T3 (en) | 2005-08-31 | 2017-04-03 | Merck Sharp & Dohme | CONSTRUCTED ANTI-IL-23 ANTIBODIES |
| DK2548577T3 (en) | 2005-12-29 | 2017-03-13 | Janssen Biotech Inc | HUMAN ANTI-IL-23 ANTIBODIES, COMPOSITIONS, PROCEDURES AND APPLICATIONS |
| CA2655372A1 (en) | 2006-06-13 | 2007-12-21 | Zymogenetics, Inc. | Il-17 and il-23 antagonists and methods of using the same |
| MX2009003982A (es) | 2006-10-20 | 2009-04-27 | Amgen Inc | Formulaciones de polipeptido estables. |
| AU2008204901A1 (en) | 2007-01-09 | 2008-07-17 | Wyeth | Anti-IL-13 antibody formulations and uses thereof |
| TWI426918B (zh) | 2007-02-12 | 2014-02-21 | Merck Sharp & Dohme | Ｉｌ-２３拮抗劑於治療感染之用途 |
| SG178804A1 (en) | 2007-02-23 | 2012-03-29 | Schering Corp | Engineered anti-il-23p19 antibodies |
| US8293883B2 (en) * | 2007-02-23 | 2012-10-23 | Schering Corporation | Engineered anti-IL-23P19 antibodies |
| EP2068923A4 (en) * | 2007-03-30 | 2010-11-24 | Medimmune Llc | ANTIBODIES HAVING REDUCED DEAMIDATION PROFILES |
| US20090208492A1 (en) * | 2007-06-14 | 2009-08-20 | Elan Pharmaceuticals, Inc. | Lyophilized Immunoglobulin Formulations and Methods of Preparation |
| WO2009114040A2 (en) | 2007-09-28 | 2009-09-17 | Centocor Ortho Biotech Inc. | Anti-il-12/23p40 antibodies, epitopes, formulations, compositions, methods and uses |
| AR068723A1 (es) | 2007-10-05 | 2009-12-02 | Glaxo Group Ltd | Proteina que se une a antigenos que se une a il-23 humana y sus usos |
| ES2511844T3 (es) | 2007-12-21 | 2014-10-23 | F. Hoffmann-La Roche Ag | Formulación de anticuerpo |
| EP2331090B1 (en) * | 2008-09-19 | 2018-01-03 | Pfizer Inc. | Stable liquid antibody formulation |
| WO2010062896A1 (en) * | 2008-11-28 | 2010-06-03 | Abbott Laboratories | Stable antibody compositions and methods for stabilizing same |
| KR20120110175A (ko) * | 2009-12-29 | 2012-10-09 | 에프. 호프만-라 로슈 아게 | 항체 제제 |
| DK2691112T3 (en) | 2011-03-31 | 2018-07-30 | Merck Sharp & Dohme | STABLE FORMULATIONS OF ANTIBODIES AGAINST HUMAN PD (PROGRAMMED DEATH) 1- RECEPTOR AND RELATED TREATMENTS |
-
2013
- 2013-09-12 UA UAA201506824A patent/UA117466C2/uk unknown
- 2013-12-09 IL IL278295A patent/IL278295B2/en unknown
- 2013-12-09 PT PT13863590T patent/PT2931313T/pt unknown
- 2013-12-09 NZ NZ708443A patent/NZ708443A/en unknown
- 2013-12-09 CA CA2894869A patent/CA2894869C/en active Active
- 2013-12-09 KR KR1020157018314A patent/KR102004585B1/ko active Active
- 2013-12-09 CN CN201380065606.7A patent/CN104870016B/zh active Active
- 2013-12-09 DK DK13863590.9T patent/DK2931313T3/da active
- 2013-12-09 TR TR2019/09584T patent/TR201909584T4/tr unknown
- 2013-12-09 BR BR112015013540-4A patent/BR112015013540B1/pt active IP Right Grant
- 2013-12-09 MX MX2015007213A patent/MX357936B/es active IP Right Grant
- 2013-12-09 LT LTEP13863590.9T patent/LT2931313T/lt unknown
- 2013-12-09 WO PCT/US2013/073825 patent/WO2014093203A1/en not_active Ceased
- 2013-12-09 MY MYPI2015701965A patent/MY187921A/en unknown
- 2013-12-09 SM SM20190414T patent/SMT201900414T1/it unknown
- 2013-12-09 PE PE2015000925A patent/PE20151524A1/es active IP Right Grant
- 2013-12-09 AU AU2013359767A patent/AU2013359767B2/en active Active
- 2013-12-09 SI SI201331504T patent/SI2931313T1/sl unknown
- 2013-12-09 PL PL13863590T patent/PL2931313T3/pl unknown
- 2013-12-09 JP JP2015547448A patent/JP6266012B2/ja active Active
- 2013-12-09 RS RS20190822A patent/RS59057B1/sr unknown
- 2013-12-09 HU HUE13863590A patent/HUE045668T2/hu unknown
- 2013-12-09 EA EA201591133A patent/EA034616B1/ru unknown
- 2013-12-09 EP EP13863590.9A patent/EP2931313B1/en active Active
- 2013-12-09 ES ES13863590T patent/ES2732861T3/es active Active
- 2013-12-09 HR HRP20191137TT patent/HRP20191137T1/hr unknown
- 2013-12-09 IL IL307581A patent/IL307581A/en unknown
-
2015
- 2015-06-02 IL IL239150A patent/IL239150B/en active IP Right Grant
- 2015-06-08 PH PH12015501296A patent/PH12015501296A1/en unknown
- 2015-06-10 CL CL2015001608A patent/CL2015001608A1/es unknown
- 2015-06-18 ZA ZA2015/04408A patent/ZA201504408B/en unknown
-
2019
- 2019-06-27 CY CY20191100675T patent/CY1121895T1/el unknown
-
2020
- 2020-12-08 US US17/114,754 patent/US20210188964A1/en active Pending
-
2024
- 2024-01-05 US US18/405,772 patent/US20240239884A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090311253A1 (en) * | 2008-06-03 | 2009-12-17 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| US20110229490A1 (en) * | 2008-08-27 | 2011-09-22 | Schering Corporation | Lyophilized Formulations of Engineered Anti-IL-23p19 Antibodies |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240239884A1 (en) | SOLUTION FORMULATIONS OF ENGINEERED ANTI-IL-23p19 ANTIBODIES | |
| JP5931442B2 (ja) | 操作された抗ＩＬ−２３ｐ１９抗体の凍結乾燥製剤 | |
| US20180008707A1 (en) | Stable liquid formulation for monoclonal antibodies | |
| JP2020500195A (ja) | アフリベルセプト製剤及びその使用 | |
| CN105051064A (zh) | 抗TNF-α抗原结合蛋白 | |
| CA2949212A1 (en) | Antibody formulation | |
| CN113453719A (zh) | 包含抗cd47抗体的制剂及其制备方法和用途 | |
| US20230173069A1 (en) | Formulation comprising anti-il-23p19 antibody, method for preparing same and use thereof | |
| JP2021503472A (ja) | 等張化剤としてリジン塩を含有するアフリベルセプト製剤及びその使用 | |
| US20210253692A1 (en) | High Concentration Liquid Antibody Formulations | |
| US12509509B2 (en) | Solution formulations of engineered anti-IL-23p19 antibodies | |
| HK1215194B (en) | Solution formulations of engineered anti-il-23p19 antibodies | |
| EP3808777A1 (en) | Stable liquid antibody formulations | |
| Elkordy¹ et al. | Application of approved and marketed products of | |
| WO2025153973A1 (en) | Highly concentrated liquid formulations for antibodies | |
| WO2020259593A1 (zh) | 包含抗lag-3抗体的制剂、其制备方法及其用途 | |
| HK40059591A (en) | Preparations containing anti-cd47 antibody, and preparation method and use therefor | |
| HK40000750A (en) | Antibody formulations |